Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Viking Therapeutics, retaining the price target of $102.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors related to Viking Therapeutics’ lead obesity program. He highlights that both Phase 3 VANQUISH trials of VK2735 have now fully enrolled, with VANQUISH-2 reaching about 1,000 type 2 diabetes patients and VANQUISH-1 enrolling roughly 4,650 non-diabetic patients, even surpassing its original target, underscoring robust demand and broad patient availability.
Pantginis also emphasizes that the rapid recruitment and large sample sizes increase confidence in the upcoming data readouts expected in the second half of 2027. He believes that, if VK2735 can show clearly better weight loss and tolerability than GLP-1–only drugs, Viking will be in a strong position for U.S. approval discussions and subsequent commercialization, supported by multiple potential paths to drive market uptake.